Detalhe da pesquisa
1.
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
Gut
; 72(3): 443-450, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36008101
2.
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Clin Gastroenterol Hepatol
; 21(13): 3365-3378.e5, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36731588
3.
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
J Pediatr Gastroenterol Nutr
; 76(4): 451-459, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36729422
4.
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn's Disease.
Dig Dis Sci
; 68(5): 1718-1727, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36436154
5.
Screening for spondyloarthritis in patients with inflammatory bowel diseases.
Rheumatol Int
; 43(1): 109-117, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36161358
6.
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Clin Gastroenterol Hepatol
; 20(9): 2074-2082, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34843987
7.
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
Am J Gastroenterol
; 117(9): 1482-1490, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35973142
8.
Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes.
Eur Radiol
; 32(4): 2813-2823, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-34657969
9.
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
Scand J Gastroenterol
; 57(12): 1454-1462, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35819361
10.
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine.
Clin Gastroenterol Hepatol
; 19(6): 1180-1188.e4, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32777552
11.
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study.
Gut
; 2020 Oct 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33106355
12.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med
; 17(10): e1003348, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33125391
13.
Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
Clin Gastroenterol Hepatol
; 18(8): 1704-1718, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31881273
14.
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
Clin Gastroenterol Hepatol
; 18(3): 637-646.e11, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31128336
15.
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.
Clin Gastroenterol Hepatol
; 18(3): 620-627.e1, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31202984
16.
Normal Lactate and Unenhanced CT-Scan Result in Delayed Diagnosis of Acute Mesenteric Ischemia.
Am J Gastroenterol
; 115(11): 1902-1905, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33156109
17.
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
Am J Gastroenterol
; 115(11): 1812-1820, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33156100
18.
Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 17(5): 905-913, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30223112
19.
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Gastroenterology
; 154(5): 1343-1351.e1, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29317275
20.
Oral Antibiotics Reduce Intestinal Necrosis in Acute Mesenteric Ischemia: A Prospective Cohort Study.
Am J Gastroenterol
; 114(2): 348-351, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30538292